Activation-specific metabolic requirements for NK cell IFN-7 production

Journal of Immunology

Volumn 194, Issue 4, 2015, Pages 1954-1962

  Keppel, Molly P ^a   Saucier, Nermina ^a   Mah, Annelise Y ^a   Vogel, Tiphanie P ^a   Cooper, Megan A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; NATURAL KILLER CELL RECEPTOR;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL METABOLISM; CONTROLLED STUDY; GLYCOLYSIS; INTERFERON PRODUCTION; METABOLIC ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; FLOW CYTOMETRY; INTERFERON-GAMMA; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84922496397     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402099     Document Type: Article

References (34)

1. Biron, C. A., and L. Brossay. 2001. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 13: 458-464.
2. French, A. R., and W. M. Yokoyama. 2003. Natural killer cells and viral infections. Curr. Opin. Immunol. 15: 45-51.
3. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
4. Lucas, M., W. Schachterle, K. Oberle, P. Aichele, and A. Diefenbach. 2007. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26: 503-517.
5. Long, E. O., H. S. Kim, D. Liu, M. E. Peterson, and S. Rajagopalan. 2013. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31: 227-258.
6. Salway, J. 2004. Metabolism at a Glance, 3rd Ed. Blackwell Publishing, Maiden, MA.
7. Porporato, P. E., S. Dhup, R. K. Dadhich, T. Copetti, and P. Sonveaux. 2011. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2: 49.
8. Schulze, A, and A. L. Harris. 2012. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491: 364-373.
9. Bremer, A. A., M. Mietus-Snyder, and R. H. Lustig. 2012. Toward a unifying hypothesis of metabolic syndrome. Pediatrics 129: 557-570.
10. Chioléro, R., J. P. Revelly, and L. Tappy. 1997. Energy metabolism in sepsis and injury. Nutrition 13: 45S-51S.
11. Pearce, E. L., M. C. Poffenberger, C. H. Chang, and R. G. Jones. 2013. Fueling immunity: insights into metabolism and lymphocyte function. Science 342: 1242454.
12. Pearce, E. L., and E. J. Pearce. 2013. Metabolic pathways in immune cell activation and quiescence. Immunity 38: 633-643.
13. Vander Heiden, M. G., L. C. Cantley, and C. B. Thompson. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
14. Fox, C. J., P. S. Hammerman, and C. B. Thompson. 2005. Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 5: 844-852.
15. Chang, C. H., J. D. Curtis, L. B. Maggi, Jr., B. Faubert, A. V. Villarino, D. O'Sullivan, S. C. Huang, G J. van der Windt, J. Blagih, J. Qiu, et al. 2013. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153: 1239-1251.
16. Overbergh, L., A. Giulietti, D. Valckx, R. Decallonne, R. Bouillon, and C. Mathieu. 2003. The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J. Biomol. Tech. 14: 33-43.
17. Marçais, A., J. Cherfils-Vicini, C. Viant, S. Degouve, S. Viel, A. Fenis, J. Rabilloud, K. Mayol, A. Tavares, J. Bienvenu, et al. 2014. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 15: 749-757.
18. Sena, L. A., S. Li, A. Jairaman, M. Prakriya, T. Ezponda, D. A. Hildeman, C. R. Wang, P. T. Schumacker, J. D. Licht, H. Perlman, et al. 2013. Mitochondria are required for anti gen-specific T cell activation through reactive oxygen species signaling. Immunity 38: 225-236.
19. He, S., K. Kato, J. Jiang, D. R. Wahl, S. Mineishi, E. M. Fisher, D. M. Murasko, G. D. Glick, and Y. Zhang. 2011. Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells. PLoS One 6: e20107.
20. Fehniger, T. A, S. F Cai, X. Cao, A. J. Bredemeyer, R. M. Presti, A. R. French, and T. J. Ley. 2007. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26: 798-811.
21. Cooper, M. A, J. E. Bush, T. A. Fehniger, J. B. VanDeusen, R. E. Waite, Y Liu, H. L. Aguila, and M. A. Caligiuri. 2002. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100: 3633-3638.
22. Koka, R., P. R. Burkett, M. Chien, S. Chai, F. Chan, J. P Lodolce, D. L. Boone, and A. Ma. 2003. Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J. Exp. Med. 197: 977-984.
23. Suck, G., V Y Oei, Y. C. Linn, S. H. Ho, S. Chu, A. Choong, M. Niam, and M. B. Koh. 2011. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp. Hematol. 39: 904-914.
24. Yokoyama, W. M. 2013. Natural killer cells. In Fundamental Immunology, 7th Ed. W. E. Paul, ed. Lippincott, Williams & Wilkins, Philadelphia, p. 395-430.
25. Cham, C. M., and T. F Gajewski. 2005. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J. Immunol. 174: 4670-4677.
26. Stetson, D. B., M. Mohrs, R. L. Reinhardt, J. L. Baron, Z. E. Wang, L. Gapin, M. Kronenberg, and R. M. Locksley. 2003. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J. Exp. Med. 198: 1069-1076.
27. Knorr, D. A., V Bachanova, M. R. Verneris, and J. S. Miller. 2014. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 26: 161-172.
28. Nandagopal, N., A. K. Ali, A. K. Komal, and S. H. Lee. 2014. The critical role of IL-15-PI3K-mTOR pathway in natural killer cell effector functions. Front. Immunol. 5: 187.
29. Waickman, A. T, and J. D. Powell. 2012. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 249: 43-58.
30. Donnelly, R. P., R. M. Loftus, S. E. Keating, K. T. Liou, C. A. Biron, C. M. Gardiner, and D. K. Finlay. 2014. mTORCl-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J. Immunol. 193: 4477-4484.
31. Vivier, E., J. A. Nunès, and F Vély. 2004. Natural killer cell signaling pathways. Science 306: 1517-1519.
32. Sun, J. C, S. Ugolini, and E. Vivier. 2014. Immunological memory within the innate immune system. EMBO J. 33: 1295-1303.
33. Cooper, M. A., and W. M. Yokoyama. 2010. Memory-like responses of natural killer cells. Immunol. Rev. 235: 297-305.
34. Kim, S., J. Poursine-Laurent, S. M. Truscott, L. Lybarger, Y J. Song, L. Yang, A. R. French, J. B. Sunwoo, S. Lemieux, T. H. Hansen, and W. M. Yokoyama. 2005. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.